Eisai Q1 Net Income Rises
rttnews·Eisai and CORE Biomedicine agree on global licence for oncology pipeline
Pharmaceutical Technology·Pfizer and Eisai Commence Co-promotion of "NURTEC(R)" for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine
Japan Corporate News·- Pfizer Japan Inc. and Eisai Co., Ltd. announced their collaboration to co-promote Nurtec® OD Tablet 75mg in Japan starting September 1, 2026, to improve migraine treatment options. - Nurtec is an oral CGRP receptor antagonist aimed at both acute treatment and prevention of migraines, addressing a significant health issue affecting millions in Japan. - This partnership combines Pfizer's development and manufacturing capabilities with Eisai's neurology expertise to enhance the dissemination of appropriate treatment information to medical institutions.AWS Announces General Availability of AWS HealthOmics in the Asia Pacific (Tokyo) Region
Press Releases·- AWS has launched AWS HealthOmics in the Asia Pacific (Tokyo) Region, a HIPAA-eligible and ISMAP-compliant bioinformatics service aimed at enhancing clinical diagnostics and drug discovery. - The service allows researchers to conduct scalable genomic analysis and integrates with AWS AI tools, with Eisai already validating its effectiveness for faster genomic analysis. - This initiative supports Japan's Genomic Medicine Promotion Act and aims to address the increasing need for advanced genomic research capabilities, contributing significantly to healthcare innovation in the region.